MS optic neuritis-induced long-term structural changes within the visual pathway.


Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
05 03 2020
Historique:
received: 08 07 2019
accepted: 22 11 2019
entrez: 1 4 2020
pubmed: 1 4 2020
medline: 7 5 2021
Statut: epublish

Résumé

The visual pathway is commonly involved in multiple sclerosis (MS), even in its early stages, including clinical episodes of optic neuritis (ON). The long-term structural damage within the visual compartment in patients with ON, however, is yet to be elucidated. Our aim was to characterize visual system structure abnormalities using MRI along with optical coherence tomography (OCT) and pattern-reversal visual evoked potentials (VEPs) depending on a single history of ON. Twenty-eight patients with clinically definitive MS, either with a history of a single ON (HON) or without such history and normal VEP findings (NON), were included. OCT measures comprised OCT-derived peripapillary retinal nerve fiber layer (RNFL) and macular ganglion cell/inner plexiform layer (GCIPL) thickness. Cortical and global gray and white matter, thalamic, and T2 lesion volumes were assessed using structural MRI. Diffusion-weighted MRI-derived measures included fractional anisotropy (FA), mean (MD), radial (RD), and axial (AD) diffusivity within the optic radiation (OR). Mean (SD) duration after ON was 8.3 (3.7) years. Compared with the NON group, HON patients showed significant RNFL ( A single history of ON induces long-term structural damage within the retina and OR suggestive of both retrograde and anterograde neuroaxonal degeneration.

Sections du résumé

BACKGROUND
The visual pathway is commonly involved in multiple sclerosis (MS), even in its early stages, including clinical episodes of optic neuritis (ON). The long-term structural damage within the visual compartment in patients with ON, however, is yet to be elucidated.
OBJECTIVE
Our aim was to characterize visual system structure abnormalities using MRI along with optical coherence tomography (OCT) and pattern-reversal visual evoked potentials (VEPs) depending on a single history of ON.
METHODS
Twenty-eight patients with clinically definitive MS, either with a history of a single ON (HON) or without such history and normal VEP findings (NON), were included. OCT measures comprised OCT-derived peripapillary retinal nerve fiber layer (RNFL) and macular ganglion cell/inner plexiform layer (GCIPL) thickness. Cortical and global gray and white matter, thalamic, and T2 lesion volumes were assessed using structural MRI. Diffusion-weighted MRI-derived measures included fractional anisotropy (FA), mean (MD), radial (RD), and axial (AD) diffusivity within the optic radiation (OR).
RESULTS
Mean (SD) duration after ON was 8.3 (3.7) years. Compared with the NON group, HON patients showed significant RNFL (
CONCLUSION
A single history of ON induces long-term structural damage within the retina and OR suggestive of both retrograde and anterograde neuroaxonal degeneration.

Identifiants

pubmed: 32224498
pii: 7/2/e665
doi: 10.1212/NXI.0000000000000665
pmc: PMC7057062
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Neuroimage. 2004 Nov;23(3):1176-85
pubmed: 15528117
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449
pubmed: 29552598
PLoS One. 2017 Aug 29;12(8):e0183957
pubmed: 28850630
BMC Neurol. 2017 Sep 5;17(1):172
pubmed: 28874119
Eur Radiol. 2015 Jan;25(1):122-31
pubmed: 25129119
J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24
pubmed: 24973342
Neurology. 2019 May 7;92(19):e2240-e2249
pubmed: 30971483
Doc Ophthalmol. 2016 Aug;133(1):1-9
pubmed: 27443562
J Neurol. 2017 Mar;264(3):520-528
pubmed: 28054131
PLoS One. 2015 Mar 25;10(3):e0122114
pubmed: 25807541
Front Neurol. 2018 Feb 27;9:92
pubmed: 29535676
Ann Neurol. 2015 Nov;78(5):801-13
pubmed: 26190464
Arch Neurol. 2009 Feb;66(2):173-9
pubmed: 19204153
Hum Brain Mapp. 2018 Apr;39(4):1712-1720
pubmed: 29334156
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
EPMA J. 2017 Jul 25;8(3):279-294
pubmed: 29021839
Ann Neurol. 2018 Feb;83(2):223-234
pubmed: 29328531
Mult Scler. 2017 Jan;23(1):43-50
pubmed: 26993116
J Clin Neurophysiol. 2006 Apr;23(2):107-10
pubmed: 16612226
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Lancet Neurol. 2010 Sep;9(9):921-32
pubmed: 20723847
Int J Mol Sci. 2016 Nov 15;17(11):
pubmed: 27854301
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1017-21
pubmed: 21297149
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Arch Neurol. 2009 May;66(5):601-9
pubmed: 19433660
Mult Scler. 2014 Dec;20(14):1904-7
pubmed: 24842962
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Radiology. 2014 Sep;272(3):832-42
pubmed: 24761837
Brain. 2006 Apr;129(Pt 4):1031-9
pubmed: 16495327
Mult Scler. 2013 Apr;19(4):443-50
pubmed: 22936335
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Arch Neurol. 2009 Aug;66(8):998-1006
pubmed: 19667222
JAMA Neurol. 2013 Jan;70(1):34-43
pubmed: 23318513
Neuroimage Clin. 2016 May 26;11:743-750
pubmed: 27330974
Brain. 2016 Mar;139(Pt 3):816-28
pubmed: 26912640
Eur J Neurol. 2013 May;20(5):803-11
pubmed: 23369013
Neuroimage. 2008 Jul 15;41(4):1324-35
pubmed: 18467131
Brain. 2001 Mar;124(Pt 3):468-79
pubmed: 11222447
Neuroimage. 2016 Jan 15;125:1079-1094
pubmed: 26549300
Clin Exp Ophthalmol. 2017 Jan;45(1):62-72
pubmed: 27011293
J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91
pubmed: 23524331
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Magn Reson Med. 1996 Dec;36(6):893-906
pubmed: 8946355
Neurology. 2005 Mar 22;64(6):1001-7
pubmed: 15781816
J Cogn Neurosci. 2007 Sep;19(9):1498-507
pubmed: 17714011
Neuroimage Clin. 2019;22:101740
pubmed: 30870736

Auteurs

Marc Pawlitzki (M)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland. marc.pawlitzki@ukmuenster.de.

Marc Horbrügger (M)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Kristian Loewe (K)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Jörn Kaufmann (J)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Roland Opfer (R)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Markus Wagner (M)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Khaldoon O Al-Nosairy (KO)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Sven G Meuth (SG)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Michael B Hoffmann (MB)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Sven Schippling (S)

From the Department of Neurology (M.P., M.H., K.L., J.K.), Otto von Guericke University, Magdeburg, Germany; Department of Neurology with Institute of Translational Neurology (M.P., S.G.M.), University Hospital Münster, Germany; Department of Computer Science (K.L.), Otto von Guericke University Magdeburg, Germany; Jung diagnostics GmbH (R.O.), Hamburg, Germany; Department of Ophthalmology (M.W., K.O.A.-N., M.B.H.), Otto von Guericke University, Magdeburg, Germany; Center of Behavioral Brain Sciences (M.B.H.), Magdeburg; Neuroimmunology and Multiple Sclerosis Research (R.O., S.S.), Department of Neurology, University Hospital Zurich, Switzerland; and Center for Neuroscience Zurich (S.S.), Federal Institute of Technology (ETH), Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH